With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We develop high-potential molecules that have compelling safety and efficacy potential, and transform them into proprietary products that enable significant advances in patient care and outcomes. We strive to meet our goals of improving patient quality of life, giving healthcare providers new treatment options, providing a collaborative environment for our employees and creating value for our shareholders.

List Labs specializes in the production of native toxins, recombinant proteins, bacterial fermentation, assay development, contract manufacturing, and biotherapeutics. List Labs produces C. difficile toxin A and toxin B, shiga toxins, cholera toxin, anthrax toxins (PA, LF, and EF), pertussis toxin, diphtheria toxin, CRM197, tetanus toxin, staphylococcal enterotoxin B, botulinum toxins as well as several types of lipopolysaccharides (LPS) or endotoxin for purchase by the research community.

Biotium is a biotechnology company that strives for innovation in biochemicals and fluorescent reagents. Innovation is at the very heart of what Biotium does every day. With 3,000+ fluorescent reagent products, a significant amount of our resources are dedicated to research and development and intellectual property protection. Our efforts have resulted in a growing number of granted and pending patents that cover a number of industry-leading technologies, including: GelRed™ and GelGreen™ nucleic acid gel stains: highly sensitive DNA/RNA gel stains made safe by preventing dye penetration into cells EvaGreen™ DNA-binding Dye: qPCR dye working on a novel “release-on-demand” DNA-binding mechanism; the only dye that works perfectly for both qPCR and highly sensitive melt curve analysis CF™ dyes: A series of 20 highly water soluble dyes with colors spanning the entire visible and near infrared spectra; designed for protein labeling using breakthrough chemistries to produce unrivaled performance in brightness and photostability Mix-n-Stain™ Antibody Labeling Kits: A revolutionary protein labeling technology that allows anyone to optimally label an antibody , with or without the presence of BSA or gelatin, with one of our CF™ dyes or biotin in 30 minutes and ~100% yield. NucView™ Caspase 3/7 Enzyme Substrate: A novel concept to detect caspase activity in live cells by releasing a cell nucleus-staining dye upon substrate cleavage AccuClear™ and AccuBlue™ DNA Quantitation Kits: Kits with the lowest dsDNA detection limit and widest linear range in the market PMA™ DNA Modification Agent: An essential reagent for selective detection of viable pathogens by qPCR

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

ReCarbon, Inc. is the creator of ReCarbon™, an innovative technology platform that recycles carbon emissions into revenue generating byproducts. We specialize in building proprietary plasma generation systems that convert industrial carbon emissions into industrial source gases. Our goal is to provide technologies that reduce carbon emissions, recycle emissions into valuable byproducts, and enable revenue growth.

Calera Corporation is dedicated to reversing global warming by capturing and permanently storing greenhouse gases in the built environment. Inspired by nature, Calera's process converts carbon dioxide (CO2) into a novel cement product at lower cost than traditional Portland cement. Calera is based in Campbell California. To learn more about Calera, please visit http://www.calera.com.

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.

Nelumbo is commercializing a new platform of structural materials. The company’s current focus is on developing improved heat exchangers for the HVAC market. Our ability to improve energy performance and minimize corrosion in a single platform unlocks mass market opportunity with potential for significant carbon emission and energy use reductions worldwide.

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA.

ReviR Therapeutics is a research and development company whose mission is to harness advanced technologies, machine learning/AI, and the inherent biology embedded within RNA to develop novel medicines to treat human disease. Our AI-based platform allows us to expand beyond the protein-based target space to reach a large number of known disease targets previously considered “undruggable” Strategies * Invent and build technologies to unlock first-in-class medicines for the treatment of cancer, rare genetic disorders, and infectious diseases * Decipher disease relevant structural and functional RNA motifs by integrating human genetic data, functional genomics, and AI * Integrate Machine Learning tools and advanced the mechanistic understanding of the RNA life cycle at scale in order to deliver transformative therapies for millions of patients

Tangible science helps patients and practitioners achieve comfort and success in specialty lenses.

Utilizing its proprietary Active Chemical Protection™ technology, GenTegra offers a suite of biomolecule stabilization products for ambient temperature storage, shipping, and processing of DNA, RNA, and fluid biospecimens. Products include applications for active stabilization of RNA viruses from swabs, saliva, fecal, and whole blood collection methodologies.